SCHEDULE: State Street Discloses 5.2% Stake in Akebia Therapeutics

State Street Corporation has reported a 5.2% beneficial ownership stake in Akebia Therapeutics Inc., holding 13,687,561 common shares as of December 31, 2025.

Summary

• State Street Corporation beneficially owns 13,687,561 shares of Akebia Therapeutics Inc. common stock.
• This ownership represents 5.2% of Akebia Therapeutics Inc.'s outstanding common stock.
• State Street Corporation holds sole voting power over 0 shares and shared voting power over 13,169,907 shares.
• State Street Corporation holds sole dispositive power over 0 shares and shared dispositive power over 13,687,561 shares.
• The filing was made by State Street Corporation as a parent holding company and through its investment adviser subsidiaries, including SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company, and State Street Global Advisors, Ltd.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive indicator, as a major institutional investor maintaining a significant stake suggests continued confidence in Akebia Therapeutics, without providing new operational insights.

Positives

• The disclosure of a significant 5.2% stake by a major institutional investor like State Street Corporation can be interpreted as a sign of institutional confidence in Akebia Therapeutics Inc.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Akebia Therapeutics Inc.'s future performance or operations.

Management Comments

• State Street Corporation certifies that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose or with the effect of changing or influencing the control of Akebia Therapeutics Inc.

Industry Context

StockSavvy.ai notes that institutional filings like this, particularly from large asset managers such as State Street Corporation, indicate significant investor interest and a stable long-term position in Akebia Therapeutics, a biotechnology company. Such disclosures are routine for institutional investors crossing the 5% ownership threshold.

Stakeholder Impact

• Shareholders may view the significant institutional ownership by State Street Corporation as a positive signal of long-term stability and confidence in Akebia Therapeutics.

Key Dates

Recommendation

The filing indicates a significant, stable institutional ownership stake by State Street Corporation in Akebia Therapeutics. While not a direct endorsement of future performance, it suggests continued institutional confidence, warranting a 'hold' for investors monitoring long-term positions.

Keywords

Akebia Therapeutics, State Street Corporation, beneficial ownership, Schedule 13G, common stock, institutional investment, biotechnology, pharmaceuticals